Literature DB >> 11181841

Characterization of the in vitro phosphorylation of human tau by tau protein kinase II (cdk5/p20) using mass spectrometry.

E T Lund1, R McKenna, D B Evans, S K Sharma, W R Mathews.   

Abstract

Hyperphosphorylated tau is an integral part of the neurofibrillary tangles that form within neuronal cell bodies, and tau protein kinase II is reported to play a role in the pathogenesis of Alzheimer's disease. Recently, we reported that tau protein kinase II (cdk5/p20)-phosphorylated human tau inhibits microtubule assembly, and tau protein kinase II (cdk5/p20) phosphorylation of microtubule-associated tau results in dissociation of phosphorylated tau from the microtubules and tubulin depolymerization. In the studies reported here, a combination of mass spectrometric techniques was used to study the phosphorylation of human recombinant tau by recombinant tau protein kinase II (cdk5/p20) in vitro. The extent of phosphorylation was determined by measuring the molecular mass of phosphorylated tau using mass spectrometry. Reaction of human recombinant tau with tau protein kinase II (cdk5/p20) resulted in the formation of two major species containing either five or six phosphate groups. The specific amino acid residues phosphorylated were determined by analyzing tryptic peptides by tandem mass spectrometry via either MALDI/TOF post-source decay or by electrospray tandem mass spectrometry. Based on these experiments, we conclude that tau protein kinase II (cdk5/p20) can phosphorylate human tau at Thr(181), Thr(205), Thr(212), Thr(217), Ser(396) and Ser(404).

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11181841     DOI: 10.1046/j.1471-4159.2001.00130.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  20 in total

Review 1.  Tau as a therapeutic target for Alzheimer's disease.

Authors:  A Boutajangout; E M Sigurdsson; P K Krishnamurthy
Journal:  Curr Alzheimer Res       Date:  2011-09       Impact factor: 3.498

Review 2.  Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.

Authors:  Yoshinari Miyata; John Koren; Janine Kiray; Chad A Dickey; Jason E Gestwicki
Journal:  Future Med Chem       Date:  2011-09       Impact factor: 3.808

Review 3.  Deregulated Cdk5 activity is involved in inducing Alzheimer's disease.

Authors:  Varsha Shukla; Susan Skuntz; Harish C Pant
Journal:  Arch Med Res       Date:  2012-11-07       Impact factor: 2.235

4.  Partial rescue of the p35-/- brain phenotype by low expression of a neuronal-specific enolase p25 transgene.

Authors:  Holger Patzke; Upendra Maddineni; Ramses Ayala; Maria Morabito; Janet Volker; Pieter Dikkes; Michael K Ahlijanian; Li-Huei Tsai
Journal:  J Neurosci       Date:  2003-04-01       Impact factor: 6.167

Review 5.  It's complicated: The relationship between sleep and Alzheimer's disease in humans.

Authors:  Brendan P Lucey
Journal:  Neurobiol Dis       Date:  2020-07-29       Impact factor: 5.996

Review 6.  Transgenic models of Alzheimer's disease: better utilization of existing models through viral transgenesis.

Authors:  Thomas L Platt; Valerie L Reeves; M Paul Murphy
Journal:  Biochim Biophys Acta       Date:  2013-04-22

7.  Cyclin-dependent kinase 5 is associated with risk for Alzheimer's disease in a Dutch population-based study.

Authors:  Alejandro Arias-Vásquez; Yurii S Aulchenko; Aaron Isaacs; Andy van Oosterhout; Kristels Sleegers; Albert Hofman; Christine van Broeckhoven; Ben A Oostra; Monique Breteler; Cornelia M van Duijn
Journal:  J Neurol       Date:  2008-03-20       Impact factor: 4.849

8.  Lithium reduces tau phosphorylation but not A beta or working memory deficits in a transgenic model with both plaques and tangles.

Authors:  Antonella Caccamo; Salvatore Oddo; Lana X Tran; Frank M LaFerla
Journal:  Am J Pathol       Date:  2007-05       Impact factor: 4.307

9.  Electrochemical investigations into kinase-catalyzed transformations of tau protein.

Authors:  Meghan K Rains; Sanela Martić; Daniel Freeman; Heinz Bernhard Kraatz
Journal:  ACS Chem Neurosci       Date:  2013-05-20       Impact factor: 4.418

Review 10.  Cdk5 as a drug target for the treatment of Alzheimer's disease.

Authors:  Lit-Fui Lau; Patricia A Seymour; Mark A Sanner; Joel B Schachter
Journal:  J Mol Neurosci       Date:  2002-12       Impact factor: 3.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.